Vaccines Market Size, Share, and Trends 2024 to 2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Vaccines Market 

5.1. COVID-19 Landscape: Vaccines Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Vaccines Market, By Type

8.1. Vaccines Market Revenue and Volume, by Type, 2024-2033

8.1.1. Recombinant/conjugate/Subunit

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Inactivated

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

8.1.3. Live Attenuated

8.1.3.1. Market Revenue and Volume Forecast (2021-2033)

8.1.4. Viral Vector

8.1.4.1. Market Revenue and Volume Forecast (2021-2033)

8.1.5. mRNA

8.1.5.1. Market Revenue and Volume Forecast (2021-2033)

8.1.6. Toxoid

8.1.6.1. Market Revenue and Volume Forecast (2021-2033)

8.1.7. Others

8.1.7.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. Global Vaccines Market, By Route of Administration

9.1. Vaccines Market Revenue and Volume, by Route of Administration, 2024-2033

9.1.1. Parenteral

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Oral

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. Global Vaccines Market, By Disease Indication 

10.1. Vaccines Market Revenue and Volume, by Disease Indication, 2024-2033

10.1.1. Viral Diseases

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Bacterial Diseases

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. Global Vaccines Market, By Age Group

11.1. Vaccines Market Revenue and Volume, by Age Group, 2024-2033

11.1.1. Pediatric

11.1.1.1. Market Revenue and Volume Forecast (2021-2033)

11.1.2. Adults

11.1.2.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 12. Global Vaccines Market, By Distribution Channel

12.1. Vaccines Market Revenue and Volume, by Distribution Channel, 2024-2033

12.1.1. Hospital & Retail Pharmacies

12.1.1.1. Market Revenue and Volume Forecast (2021-2033)

12.1.2. Government Suppliers

12.1.2.1. Market Revenue and Volume Forecast (2021-2033)

12.1.3. Others

12.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 13. Global Vaccines Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Type (2021-2033)

13.1.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

13.1.3. Market Revenue and Volume Forecast, by Disease Indication (2021-2033)

13.1.4. Market Revenue and Volume Forecast, by Age Group (2021-2033)

13.1.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)

13.1.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

13.1.6.3. Market Revenue and Volume Forecast, by Disease Indication (2021-2033)

13.1.6.4. Market Revenue and Volume Forecast, by Age Group (2021-2033)

13.1.6.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033) 

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Type (2021-2033)

13.1.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

13.1.7.3. Market Revenue and Volume Forecast, by Disease Indication (2021-2033)

13.1.7.4. Market Revenue and Volume Forecast, by Age Group (2021-2033)

13.1.7.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Type (2021-2033)

13.2.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

13.2.3. Market Revenue and Volume Forecast, by Disease Indication (2021-2033)

13.2.4. Market Revenue and Volume Forecast, by Age Group (2021-2033) 

13.2.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033) 

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)

13.2.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

13.2.6.3. Market Revenue and Volume Forecast, by Disease Indication (2021-2033)

13.2.7. Market Revenue and Volume Forecast, by Age Group (2021-2033) 

13.2.8. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033) 

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Type (2021-2033)

13.2.9.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

13.2.9.3. Market Revenue and Volume Forecast, by Disease Indication (2021-2033)

13.2.10. Market Revenue and Volume Forecast, by Age Group (2021-2033)

13.2.11. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Type (2021-2033)

13.2.12.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

13.2.12.3. Market Revenue and Volume Forecast, by Disease Indication (2021-2033)

13.2.12.4. Market Revenue and Volume Forecast, by Age Group (2021-2033)

13.2.13. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Type (2021-2033)

13.2.14.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

13.2.14.3. Market Revenue and Volume Forecast, by Disease Indication (2021-2033)

13.2.14.4. Market Revenue and Volume Forecast, by Age Group (2021-2033)

13.2.15. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Type (2021-2033)

13.3.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

13.3.3. Market Revenue and Volume Forecast, by Disease Indication (2021-2033)

13.3.4. Market Revenue and Volume Forecast, by Age Group (2021-2033)

13.3.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)

13.3.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

13.3.6.3. Market Revenue and Volume Forecast, by Disease Indication (2021-2033)

13.3.6.4. Market Revenue and Volume Forecast, by Age Group (2021-2033)

13.3.7. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Type (2021-2033)

13.3.8.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

13.3.8.3. Market Revenue and Volume Forecast, by Disease Indication (2021-2033)

13.3.8.4. Market Revenue and Volume Forecast, by Age Group (2021-2033)

13.3.9. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Type (2021-2033)

13.3.10.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

13.3.10.3. Market Revenue and Volume Forecast, by Disease Indication (2021-2033)

13.3.10.4. Market Revenue and Volume Forecast, by Age Group (2021-2033)

13.3.10.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Type (2021-2033)

13.3.11.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

13.3.11.3. Market Revenue and Volume Forecast, by Disease Indication (2021-2033)

13.3.11.4. Market Revenue and Volume Forecast, by Age Group (2021-2033)

13.3.11.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)

13.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

13.4.3. Market Revenue and Volume Forecast, by Disease Indication (2021-2033)

13.4.4. Market Revenue and Volume Forecast, by Age Group (2021-2033)

13.4.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)

13.4.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

13.4.6.3. Market Revenue and Volume Forecast, by Disease Indication (2021-2033)

13.4.6.4. Market Revenue and Volume Forecast, by Age Group (2021-2033)

13.4.7. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Type (2021-2033)

13.4.8.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

13.4.8.3. Market Revenue and Volume Forecast, by Disease Indication (2021-2033)

13.4.8.4. Market Revenue and Volume Forecast, by Age Group (2021-2033)

13.4.9. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Type (2021-2033)

13.4.10.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

13.4.10.3. Market Revenue and Volume Forecast, by Disease Indication (2021-2033)

13.4.10.4. Market Revenue and Volume Forecast, by Age Group (2021-2033)

13.4.10.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Type (2021-2033)

13.4.11.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

13.4.11.3. Market Revenue and Volume Forecast, by Disease Indication (2021-2033)

13.4.11.4. Market Revenue and Volume Forecast, by Age Group (2021-2033)

13.4.11.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

13.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

13.5.3. Market Revenue and Volume Forecast, by Disease Indication (2021-2033)

13.5.4. Market Revenue and Volume Forecast, by Age Group (2021-2033)

13.5.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)

13.5.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

13.5.6.3. Market Revenue and Volume Forecast, by Disease Indication (2021-2033)

13.5.6.4. Market Revenue and Volume Forecast, by Age Group (2021-2033)

13.5.7. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Type (2021-2033)

13.5.8.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

13.5.8.3. Market Revenue and Volume Forecast, by Disease Indication (2021-2033)

13.5.8.4. Market Revenue and Volume Forecast, by Age Group (2021-2033)

13.5.8.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

Chapter 14. Company Profiles

14.1. GSK plc

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Merck & Co Inc

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Pfizer Inc

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Sanofi

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. CSL (Australia), Emergent

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Johnson and Johnson Services, Inc.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Astrazeneca

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Serum Institute of India Pvt Ltd

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Bavarian Nordic

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Mitsubishi Tanabe Pharma Corporation

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms